NCT03639714View on ClinicalTrials.gov

A Study of a Personalized Neoantigen Cancer Vaccine

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 13, 2019

Primary Completion Date

November 10, 2022

Study Completion Date

November 10, 2022

Conditions
Non Small Cell Lung CancerColorectal CancerGastroesophageal AdenocarcinomaUrothelial Carcinoma
Interventions
BIOLOGICAL

GRT-C901

a patient-specific neoantigen cancer vaccine prime

BIOLOGICAL

GRT-R902

a patient-specific neoantigen cancer vaccine boost

BIOLOGICAL

nivolumab

anti-PD-1 monoclonal antibody

BIOLOGICAL

ipilimumab

anti-CTLA-4 monoclonal antibody

Trial Locations (11)

3000

Peter MacCallum Cancer Centre, Melbourne

10017

Memorial Sloan Kettering Cancer Center, New York

10032

Columbia University Medical Center, New York

22031

Virginia Cancer Specialists, Fairfax

32224

Mayo Clinic, Jacksonville

37203

Tennessee Oncology, Nashville

43210

The Ohio State University Comprehensive Cancer Center, Columbus

55905

Mayo Clinic, Rochester

60637

The University of Chicago, Chicago

77030

MD Anderson Cancer Center, Houston

85054

Mayo Clinic Arizona, Phoenix

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Gritstone bio, Inc.

INDUSTRY

NCT03639714 - A Study of a Personalized Neoantigen Cancer Vaccine | Biotech Hunter | Biotech Hunter